Major Depressive Disorder, Marijuana, and Cannabinoids: Disentangling the Research to Help You Guide Your Patients-Presentation Slides

Presentation Slides

Pdf Summary

The document is a summary titled "Major Depressive Disorder, Marijuana, and Cannabinoids: Disentangling the Research to Help You Guide Your Patients." It is an initiative by the American Psychiatric Association (APA) and the Substance Abuse and Mental Health Services Administration (SAMHSA). The summary provides an overview of the research on the use of marijuana and cannabinoids in relation to Major Depressive Disorder (MDD).<br /><br />The document begins by introducing the Clinical Support System for Serious Mental Illness (CSS-SMI), which is a SAMHSA-funded initiative implemented by the APA. It then presents the learning objectives of the activity, which include critically reviewing research on cannabinoids, educating patients on the addictive potential of high THC products, and counseling MDD patients on the risks of using cannabis.<br /><br />The summary discusses the background of support for cannabis, including its legal status in many states and reported improvements in chronic pain, anxiety, and depression. It also highlights the problems associated with cannabis, such as the potential for addiction and the development of cannabis use disorder.<br /><br />The document provides an overview of the endocannabinoid system (ECS), major cannabinoid classes, cannabis plant preparations, and the addictive potential of cannabis. It also discusses state laws regarding medical and recreational cannabis use.<br /><br />The summary delves into the relationship between the ECS and mood regulation, highlighting studies that suggest an association between decreased ECS signaling and the development of depressive episodes. It then explores the effects of consumed cannabinoids on mood, with a focus on THC and CBD. Highly addictive cannabinoids, such as whole cannabis and THC concentrates, are found to increase the risk of MDD and exacerbate symptoms, while the effects of less addictive cannabinoids, such as CBD concentrates and pharmaceutical-grade THC/THC analogues, are less clear.<br /><br />In summary, the document provides an overview of the current research on the use of marijuana and cannabinoids in relation to Major Depressive Disorder, highlighting the potential risks and benefits.

Keywords

Major Depressive Disorder

Marijuana

Cannabinoids

Research

Clinical Support System for Serious Mental Illness

Addictive Potential

High THC Products

Cannabis Use Disorder

Endocannabinoid System

Mood Regulation